Sierra ICC profiles generated by FFEI colour calibration products can now be imported into Visiopharm to ensure ground-truth colour standardisation of digital samples
November 26th 2021 FFEI Ltd, the global developer of award-winning digital pathology imaging solutions, today announced that their patented Sierra colour calibration technology has been integrated into Visiopharm’s viewer, for AI-based image analysis and workflow. Visiopharm is on a mission to transform pathology through AI and workflow standardisation. Today this goes a step further by enabling pathologists to view digital tissue samples that are standardised to ground truth colour – using scanner agnostic, device-specific ICC profiles.
The ICC profile is seamlessly generated using the recently launched Sierra Validate & Standardise (VS) Profiler. Available as a package, Sierra VS-Profiler comprises of a Sierra slide, Sierra VS-Analyser tool and FFEI’s proprietary algorithm that will generate high-accuracy, device-specific ICC profiles. Specifically, the accuracy of a given scanner is measured using an image of the patented Sierra slide. A unique ICC profile is then generated for that device to be integrated into manufacturing, QA process, AI systems and other workflows.
It is this ICC profile that can now be integrated into Visiopharm’s pathology workflow and will enable all images scanned to remain standardised and of ground truth colour when viewed using the Visiopharm Viewer platform. For pathologists they simply need to upload the ICC profile to Visiopharm.
Dr Rick Salmon commented: “With an increasing demand for standardisation across the digital pathology landscape, we are excited that industry innovators such as Visiopharm are embracing the specific need to standardise colour – incorporating FFEI’s patented Sierra technology, quantitative analysis and high-accuracy ICC profiling algorithm into Visiopharm’s industry-leading viewer.” Dr Salmon continued, “This collaboration represents a first-in-kind, scanner-agnostic solution to a key QA issue for current and future users.”
“With this important milestone for scanner agnostic calibration and troubleshooting, Visiopharm underpins their leading position in the field of digital pathology and becomes the first company supporting FFEI ICC profiling,” said Visiopharm chief technology officer, Johan Doré.
Visiopharm® is a world leader in AI-driven digital pathology solutions. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.
AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, Netherlands, and the United States. For more information, visit Visiopharm.com
FFEI is a leading developer, manufacturer, and supplier of digital imaging solutions within the life science and graphic arts industries. With over 70 years invested in digital imaging technology, FFEI has an impressive reputation for developing innovative and award-winning solutions – from concept to delivery.
FFEI’s market-leading expertise and knowledge has established them as a key supplier of OEM products and integrated technologies to world-class partners across both the digital inkjet and life science sectors. Whether the challenge is to create software functions to enhance a workflow; accurately jet billions of ink droplets a second on to exotic materials; or even create ultra-high resolution micro scanning mechanisms to research human tissue – FFEI has that capability.
Please visit http://www.ffei.ai
For further information, please contact:
+44 (0) 1442 210456